Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $6.78
Previous CloseN/A
Volume194.31K
Average Volume (3M)701.99K
Market Cap
$112.96M
Enterprise Value-$185.05M
Total Cash (Recent Filing)$32.45M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 01, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding99,085,890
10 Day Avg. Volume933,282
30 Day Avg. Volume701,988
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.33
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.84
Enterprise Value/Ebitda1.34
Forecast
1Y Price Target
$4.50Price Target Upside294.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Alector News
PremiumCompany Announcements
Alector Announces Resignation of Chief Medical Officer
PremiumCompany Announcements
Alector’s Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Alector’s 2024 Financial Results and Clinical Advancements
---
Bulls Say, Bears Say
Bulls Say
Commercial PotentialThe near 100% penetrance for developing FTD-GRN following PGRN mutations suggests a direct causal link, positioning PGRN-targeting latozinemab for meaningful commercial upside.
Financial StabilityThe company reported cash through 2026, indicating strong financial stability.
Pipeline DevelopmentAlector continues to develop its preclinical pipeline with plans to advance the ABC-GCase asset ADP050-ABC and anti-Aβ antibody asset ADP037-ABC into the clinic.
Bears Say
Competitive ChallengesCrowding and competition are expected to be an issue in Alector's efforts.
Financial ConcernsFY25 net cash loss continues to be aggressive given extensive R&D and manufacturing platform.
Stock Performance OutlookAlector is assumed at an Underweight rating, indicating a cautious outlook on the stock's performance.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $6.78 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $112.96M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is May 01, 2025 which is in 4 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Feb 26, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.623 by $0.603.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.48.
How many shares outstanding does Alector Inc have?
Alector Inc has 99,085,890 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.623. Following the earnings report the stock price went down -3.488%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
---
Alector Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (294.74% Upside)
$4.50 (294.74% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 8.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $151.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.29%
12-Months-Change
Fundamentals
Return on Equity
-91.24%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
---
ALEC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, increased collaboration revenue for the quarter, and a strong cash position. However, minimal year-over-year revenue growth and sustained high R&D expenses present challenges.Read More>---
ALEC Stock 12 Month Forecast
Average Price Target
$4.50
▲(294.74% Upside)
Technical Analysis
Coherus Biosciences
―
Enanta Pharmaceuticals
―
XBiotech
―
C4 Therapeutics
―
Instil Bio
―
Best Analysts Covering ALEC
1 Year
1 Year Success Rate
4/14 ratings generated profit
1 Year Average Return
-23.76%
reiterated a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -23.76% per trade.
---